Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Never miss an Options trading signal: Unusual Options Activity and Options Screeners with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Oncolytics Biotech Inc (ONCY)

Oncolytics Biotech Inc (ONCY)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 97,350
  • Shares Outstanding, K 100,361
  • Annual Sales, $ 0 K
  • Annual Income, $ -23,140 K
  • EBIT $ -25 M
  • EBITDA $ -25 M
  • 60-Month Beta 0.88
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book N/A
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -0.28
  • Most Recent Earnings $-0.10 on 11/12/25
  • Next Earnings Date 03/06/26
  • Annual Dividend & Yield 0.00 (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sector Medical
  • INDUSTRY GROUPING Medical - Biomedical

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 8 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/25
See More
  • Average Estimate -0.06
  • Number of Estimates 1
  • High Estimate -0.06
  • Low Estimate -0.06
  • Prior Year -0.07
  • Growth Rate Est. (year over year) +14.29%

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.8614 +11.96%
on 11/28/25
1.0600 -9.02%
on 12/17/25
-0.0756 (-7.27%)
since 11/26/25
3-Month
0.8614 +11.96%
on 11/28/25
1.5100 -36.13%
on 09/29/25
-0.3256 (-25.24%)
since 09/26/25
52-Week
0.3258 +196.01%
on 06/06/25
1.5100 -36.13%
on 09/29/25
-0.0365 (-3.65%)
since 12/26/24

Most Recent Stories

More News
Stocks in play: Oncolytics Biotech Inc

Announced clinical and translational findings supporting the development of pelareorep in second-line ...

ONCY : 0.9600 (-1.03%)
Pivotal Cancer Trials Gain Momentum as Regulatory Clarity Emerges

Issued on behalf of Oncolytics Biotech Inc. VANCOUVER – Baystreet.ca News Commentary – The FDA issued multiple breakthrough approvals for oncology drugs in November 2025, marking a transformative...

ONCY : 0.9600 (-1.03%)
ZNTL : 1.3400 (-2.90%)
NUVB : 9.35 (-1.79%)
OSTX : 1.5000 (-1.32%)
MAIA : 1.4600 (-1.35%)
Oncolytics Biotech® Announces Promising Efficacy and Translational Data Supporting Pelareorep in KRAS-Mutant Metastatic Colorectal Cancer

33% ORR achieved in second-line KRAS-mutant MSS colorectal cancer—triple historical response rates for Avastin + FOLFIRI of 6-11% Translational analysis shows pelareorep...

ONCY : 0.9600 (-1.03%)
Platform Oncology Technologies Drive Multi-Indication Treatment Expansion

Issued on behalf of Oncolytics Biotech Inc. VANCOUVER – Baystreet.ca News Commentary – Artificial intelligence and platform-based approaches reshaped cancer treatment development in November...

ONCY : 0.9600 (-1.03%)
SANA : 4.39 (-3.09%)
ABSI : 3.52 (-1.12%)
RXRX : 4.25 (-3.41%)
TEM : 63.01 (-1.95%)
Oncolytics Biotech® Reschedules Special Meeting of Shareholders to Change Jurisdiction of Incorporation to Nevada

Oncolytics Biotech ® Inc. (Nasdaq: ONCY) (“ Oncolytics ” or the “ Company ”), a clinical-stage immunotherapy company developing pelareorep, today announced...

ONCY : 0.9600 (-1.03%)
Oncolytics Biotech® Provides Update on Special Meeting of Shareholders

Oncolytics Biotech ® Inc. (Nasdaq: ONCY) (“ Oncolytics ” or the “ Company ”), a clinical-stage immunotherapy company developing pelareorep, today announced...

ONCY : 0.9600 (-1.03%)
Stocks in play: Oncolytics Biotech Inc

Announced alignment with the U.S. Food and Drug Administration regarding the design of its pivotal study ...

ONCY : 0.9600 (-1.03%)
Targeted Cancer Therapies Gain Momentum as Precision Market Surges Past $106B

EQNX::TICKER_START (NASDAQ:ONCY),(NASDAQ:ALXO),(NASDAQ:ERAS),(NASDAQ:IMRX),(NASDAQ:PRLD) EQNX::TICKER_END

ONCY : 0.9600 (-1.03%)
IMRX : 6.72 (-1.32%)
ALXO : 1.3200 (-2.94%)
ERAS : 3.45 (+0.58%)
PRLD : 2.28 (+2.24%)
Targeted Cancer Therapies Gain Momentum as Precision Market Surges Past $106B

PALM BEACH, Fla., Nov. 19, 2025 (GLOBE NEWSWIRE) -- FN Media Group News Commentary - The precision oncology sector is experiencing unprecedented transformation as biomarker-driven therapies and...

ONCY : 0.9600 (-1.03%)
IMRX : 6.72 (-1.32%)
ALXO : 1.3200 (-2.94%)
ERAS : 3.45 (+0.58%)
PRLD : 2.28 (+2.24%)
Oncolytics Biotech® Aligns with FDA on Pivotal Study Design for Pelareorep in First-Line Pancreatic Cancer

Company to launch only current registration trial with an immunotherapy in first-line pancreatic cancer in first half of 2026 Trial design allows flexibility to include...

ONCY : 0.9600 (-1.03%)

Business Summary

Oncolytics Biotech, Inc. focuses on the discovery and development of pharmaceutical products for the treatment of a wide variety of human and companion pet cancers. The Company was formed to explore the oncolytic capability of the reovirus, a virus that preferentially replicates in cells with an activated...

See More

Key Turning Points

3rd Resistance Point 1.0198
2nd Resistance Point 1.0099
1st Resistance Point 0.9899
Last Price 0.9600
1st Support Level 0.9600
2nd Support Level 0.9501
3rd Support Level 0.9301

See More

52-Week High 1.5100
Fibonacci 61.8% 1.0576
Last Price 0.9600
Fibonacci 50% 0.9179
Fibonacci 38.2% 0.7782
52-Week Low 0.3258

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar